Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

P Peterlongo, J Chang-Claude, KB Moysich, A Rudolph, RK Schmutzler, J Simard, P Soucy, RA Eeles, DF Easton, U Hamann, S Wilkening, BW Chen, MA Rookus, MK Schmidt, FH van der Baan, AB Spurdle, LC Walker, F Lose, AT Maia, M MontagnaL Matricardi, J Lubinski, A Jakubowska, EBG Garcia, OI Olopade, RL Nussbaum, KL Nathanson, SM Domchek, TR Rebbeck, BK Arun, BY Karlan, S Orsulic, J Lester, WK Chung, A Miron, MC Southey, DE Goldgar, SS Buys, R Janavicius, CM Dorfling, EJ van Rensburg, YC Ding, SL Neuhausen, TVO Hansen, AM Gerdes, B Ejlertsen, L Jonson, A Osorio, C Martinez-Bouzas, J Benitez, EE Conway, KR Blazer, JN Weitzel, S Manoukian, B Peissel, D Zaffaroni, G Scuvera, M Barile, F Ficarazzi, F Mariette, S Fortuzzi, A Viel, G Giannini, L Papi, A Martayan, MG Tibiletti, P Radice, A Vratimos, F Fostira, JE Garber, A Donaldson, C Brewer, C Foo, DGR Evans, D Frost, D Eccles, A Brady, J Cook, M Tischkowitz, J Adlard, J Barwell, L Walker, L Izatt, LE Side, MJ Kennedy, MT Rogers, ME Porteous, PJ Morrison, R Platte, R Davidson, SV Hodgson, S Ellis, T Cole, AK Godwin, K Claes, T Van Maerken, A Meindl, A Gehrig, C Sutter, C Engel, D Niederacher, D Steinemann, H Plendl, K Kast, K Rhiem, N Ditsch, N Arnold, R Varon-Mateeva, B Wappenschmidt, S Wang-Gohrke, B Bressac-de Paillerets, B Buecher, C Delnatte, C Houdayer, D Stoppa-Lyonnet, F Damiola, I Coupier, L Barjhoux, L Venat-Bouvet, L Golmard, N Boutry-Kryza, OM Sinilnikova, O (Olivier) Caron, P Pujol, S Mazoyer, M Belotti, M Piedmonte, ML Friedlander, GC Rodriguez, LJ Copeland, M de la Hoya, PP Segura, H Nevanlinna, K Aittomaki, TAM van Os, HEJ Meijers-Heijboer, AH van der Hout, MPG Vreeswijk, N Hoogerbrugge, MGEM Ausems, Lena van Doorn, Margriet Collee, E Olah, O Diez, I Blanco, C (Conxi) Lazaro, J Brunet, L Feliubadalo, C Cybulski, J Gronwald, K Durda, K Jaworska-Bieniek, G Sukiennicki, A Arason, J Chiquette, MR Teixeira, C Olswold, FJ Couch, NM Lindor, XS Wang, CI Szabo, K Offit, M Corines, L Jacobs, ME Robson, LY Zhang, V Joseph, A Berger, CF Singer, C Rappaport, DG Kaulich, G Pfeiler, MKM Tea, CM Phelan, MH Greene, PL Mai, G Rennert, AM Mulligan, G Glendon, S Tchatchou, IL Andrulis, AE Toland, A Bojesen, IS Pedersen, Marga Thomassen, UB Jensen, Y Laitman, J Rantala, A von Wachenfeldt, H Ehrencrona, MS Askmalm, A Borg, KB Kuchenbaecker, L McGuffog, D Barrowdale, S Healey, A van der Lee, PDP Pharoah, G Chenevix-Trench, AC Antoniou, E Friedman

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Scopus)


Background: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes. Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach. Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies. (C)2014 AACR.
Original languageUndefined/Unknown
Pages (from-to)308-316
Number of pages9
JournalCancer Epidemiology Biomarkers & Prevention
Issue number1
Publication statusPublished - 2015

Cite this